Processa Pharmaceuticals, Inc. (PCSA) — SEC Filings
Processa Pharmaceuticals, Inc. (PCSA) — 50 SEC filings. Latest: 10-K/A (Apr 30, 2026). Includes 31 8-K, 5 10-Q, 3 DEF 14A.
View Processa Pharmaceuticals, Inc. on SEC EDGAR
Overview
Processa Pharmaceuticals, Inc. (PCSA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 15, 2025: Processa Pharmaceuticals, Inc. filed an 8-K on December 15, 2025, reporting events as of December 12, 2025. The filing indicates material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. It also includes financial statements and exhibits.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 4 bearish, 45 neutral, 1 mixed. The dominant filing sentiment for Processa Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Processa Pharmaceuticals, Inc. (PCSA) has filed 1 4, 1 10-K/A, 31 8-K, 5 10-Q, 2 8-K/A, 3 DEF 14A, 2 S-1, 2 10-K, 3 S-1/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PCSA's 42 recent filings, 5 were flagged as high-risk, 19 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$3,436,573 |
| EPS | -$0.41 |
| Debt-to-Equity | N/A |
| Cash Position | $6,308,420 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- George Ng
- Wendy Guy
- Board of Directors
- Michael B. Kirwan
- Robert F. Charron, Esq.
- John J. Wolfel, Jr.
- John J. Hart, Esq.
- Neda Sharifi
- David Young
- Neda Sharifi Foley
- Dr. Michael H. Smith
- Dr. David J. Gury
Industry Context
The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies like PCSA compete in a landscape where innovation is key, but success is often uncertain due to clinical trial outcomes and market adoption. The industry is also seeing increasing interest in novel therapeutic areas and digital health solutions.
Top Tags
corporate-governance (8) · disclosure (7) · pharmaceuticals (7) · 8-K (6) · filing (5) · sec-filing (5) · material-agreement (5) · financials (5) · shareholder-vote (4) · 10-Q (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $10.2M | Increased from $9.1M for the nine months ended September 30, 2024, indicating widening operational losses. |
| Cash and Cash Equivalents | $6.3M | Increased significantly from $1.2M at December 31, 2024, primarily due to financing activities. |
| Accumulated Deficit | $97.4M | Increased from $87.2M at December 31, 2024, reflecting ongoing losses since inception. |
| Net Cash Used in Operating Activities | $8.5M | For the nine months ended September 30, 2025, demonstrating continued cash burn from operations. |
| Net Proceeds from Stock Sales and Warrants | $13.6M | Key source of liquidity for the nine months ended September 30, 2025, highlighting reliance on dilutive financing. |
| Digital Assets Held | $350K | New strategic investment in USD-backed stablecoins as of September 30, 2025. |
| Outstanding Shares | 56,644,223 | As of November 3, 2025, indicating significant dilution from prior periods. |
| Net Loss per Share (Diluted) | $0.41 | For the nine months ended September 30, 2025, lower than $3.13 in 2024 due to increased share count. |
| Commission File Number | 001-39531 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 45-1539785 | Company's tax identification number |
| Current authorized common stock | 100,000,000 shares | Proposed to increase to 1,000,000,000 shares |
| Proposed authorized common stock | 1,000,000,000 shares | A 900% increase from current levels |
| Minimum reverse stock split ratio | 1-for-2 | Board discretion for reverse stock split |
| Maximum reverse stock split ratio | 1-for-50 | Board discretion for reverse stock split |
| Date of Special Meeting | September 2, 2025 | Stockholders to vote on proposals |
Frequently Asked Questions
What are the latest SEC filings for Processa Pharmaceuticals, Inc. (PCSA)?
Processa Pharmaceuticals, Inc. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 31 8-K, 5 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PCSA filings?
Across 50 filings, the sentiment breakdown is: 4 bearish, 45 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Processa Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Processa Pharmaceuticals, Inc. (PCSA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Processa Pharmaceuticals, Inc.?
Key financial highlights from Processa Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PCSA?
The investment thesis for PCSA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Processa Pharmaceuticals, Inc.?
Key executives identified across Processa Pharmaceuticals, Inc.'s filings include George Ng, Wendy Guy, Board of Directors, Michael B. Kirwan, Robert F. Charron, Esq. and 7 others.
What are the main risk factors for Processa Pharmaceuticals, Inc. stock?
Of PCSA's 42 assessed filings, 5 were flagged high-risk, 19 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Processa Pharmaceuticals, Inc.?
Forward guidance and predictions for Processa Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.